Citations

Showing 10 of 108094 citations.

Bronchiolar Adenoma
Borsu, Laetitia , Lu, Shaohua, Larsen, Brandon T. , Sae‐Ow, Wichit, Mackinnon, Alexander C. , Bowman, Anita S. , Arcila, Maria E. , Ladanyi, Marc , Chang, Jason C. , Montecalvo, Joseph , Wallace, William D. , Kim, Hyunjae Ryan , Sauter, Jennifer L. , Travis, William D. , Rekhtman, Natasha

Mayo Clinic

American Journal of Surgical Pathology | May 24, 2018 | Volume: 42 | Issue: 8 | Pages: 1010-1026

10.1097/pas.0000000000001086 | PMID 29846186 Get It

We have identified 25 lesions involving alveolar lung parenchyma characterized by nodular proliferation of bland bilayered bronchiolar-type epithelium containing a continuous layer of basal cells. These lesions shared some histologic features with the recently described entity of ciliated muconodular papillary tumor (CMPT); however, the majority did not fit all diagnostic criteria in that they exhibited only focal or absent papillary architecture, and they had variable number of ciliated and mucinous cells, with some lesions entirely lacking 1 or both of these components. The morphologic and immunohistochemical features ranged from those resembling proximal bronchioles (proximal-type: moderate to abundant mucinous and ciliated cells; negative or weak TTF1 in luminal cells; n=8) to those resembling respiratory bronchioles (distal-type: scant or absent mucinous and ciliated cells; positive TTF1 in luminal cells; n=17). The hallmark of all lesions was a continuous layer of basal cells (p40 and CK5/6-positive). We provisionally designated these lesions as bronchiolar adenomas (BAs) and analyzed their clinicopathologic and molecular features. All BAs were discrete, sharply circumscribed lesions with a median size of 0.5 cm (range, 0.2 to 2.0 cm). Most lesions were either entirely flat (n=14) or contained focal papillary architecture (n=7); only 4 lesions, all proximal-type, were predominantly papillary, fitting the classic description of CMPT. Notably, of 9 lesions submitted for frozen section evaluation, 7 were diagnosed as adenocarcinoma. No postsurgical recurrences were observed for any lesions (median follow-up, 11 mo). Twenty-one BAs underwent next-generation sequencing and/or immunohistochemistry for BRAF V600E, revealing mutation profiles similar to those previously described for CMPTs, including BRAF V600E mutations (n=8, 38%), unusual EGFR exon 19 deletions (n=2, 10%), EGFR exon 20 insertions (n=2, 10%), KRAS mutations (n=5, 24%), and HRAS mutations (n=1, 5%). The mutation profiles were similar in proximal-type and distal-type lesions. In conclusion, we describe a family of putatively benign clonal proliferations with a spectrum of morphology recapitulating various levels of the bronchiolar tree, of which only a minor subset fits the classic description of CMPT. Comparable mutation profiles and partially overlapping morphologic features across the spectrum of these lesions support their nosological relationship. We propose designating this entire family of lesions as BAs, and that lesions currently designated CMPTs represent a subgroup of this family.
Anatomy of the deep venous system in vein of Galen malformation and its changes after endovascular treatment depicted by magnetic resonance venography
Winkler, Olivia, Brinjikji, Waleed , Brassel, Friedhelm , Meila, Dan , Lanfermann, Heinrich

Mayo Clinic

Journal of NeuroInterventional Surgery | May 24, 2018 | Volume: 11 | Issue: 1 | Pages: 84-89

10.1136/neurintsurg-2018-013789 | PMID 29794159 Get It

Background and purpose It is classically thought that the internal cerebral veins (ICV) do not communicate with the venous pouch of vein of Galen malformations (VGM). We report on the anatomy of the deep venous system in VGM with special emphasis on the drainage of the ICV and possible changes after endovascular treatment. Materials and methods We retrospectively analyzed DSA and 2D time-of-flight MR venograms of 55 children with VGM. We evaluated all pre- and post-operative images for the presence of the ICVs and determined their route of venous drainage. Results Of 55 children, pre-operative 2D MRV detected the ICVs in 19 cases (35%) compared with one case (2%) for pre-embolization DSA (2%) (P<0.0001). Of the cases in which the ICVs were seen preoperatively, in 15 cases (78.9%) the ICV drained directly into the VGM while in the other four cases, the ICV used alternative venous drainage routes. On post-operative MRV, the ICVs were seen in 17 cases (31%) on MRV and 10 cases (18.2%) on DSA with drainage into an adult-like vein of Galen in 13 cases (76%), respectively (P=0.08). In four cases normal ICV drainage into the vein of Galen was seen even when the venous sac was closed. In two cases there was a change in ICV drainage from the vein of Galen to the lateral mesencephalic vein. Conclusion The communication of the ICV with the VGM is a common phenomenon. Different changes of venous drainage routes do occur after treatment and are best seen on MRV.
Anti‐viral therapy is associated with improved survival but is underutilised in patients with hepatitis B virus‐related hepatocellular carcinoma: real‐world east and west experience
Chen, Vincent , Yeh, Ming-Lun, Le, An K. , Jun, Mi Jung, Saeed, Waqar Khalid , Yang, Ju Dong , Huang, Chung‐Feng , Lee, H. Y., Tsai, Pei‐Chien , Giama, Nasra H., Kim, N. G., Nguyen, Phuong , Dang, Hansen , Ali, Hamdi A. , Zhang, N., Chuang, Wan‐Long , Roberts, Lewis R. , Yu, Ming‐Lung , Nguyen, Mindie H. , Chen, V L , Huang, C-F , Jun, D W , Yu, M-L , Nguyen, Mindie H , Roberts, Lewis R , Yeh, Ming-Lun , Yang, Ju Dong , Lee, M.‐H., Huang, Jee‐Fu , Dai, Chia-Yen , Lim, Young‐Suk

Mayo Clinic

Alimentary Pharmacology & Therapeutics | May 24, 2018 | Volume: 48 | Issue: 1 | Pages: 44-54

10.1111/apt.14801 | PMID 29797518 Get It

SummaryBackgroundHepatitis B virus (HBV) is the leading cause of hepatocellular carcinoma (HCC) worldwide. It remains incompletely understood in the real world how anti‐viral therapy affects survival after HCC diagnosis.MethodsThis was an international multicentre cohort study of 2518 HBV‐related HCC cases diagnosed between 2000 and 2015. Cox proportional hazards models were utilised to estimate hazard ratios (HR) with 95% (CI) for anti‐viral therapy and cirrhosis on patients' risk of death.ResultsApproximately, 48% of patients received anti‐viral therapy at any time, but only 17% were on therapy at HCC diagnosis (38% at US centres, 11% at Asian centres). Anti‐viral therapy would have been indicated for >60% of the patients not on anti‐viral therapy based on American criteria. Patients with cirrhosis had lower 5‐year survival (34% vs 46%; P < 0.001) while patients receiving anti‐viral therapy had increased 5‐year survival compared to untreated patients (42% vs 25% with cirrhosis and 58% vs 36% without cirrhosis; P < 0.001 for both). Similar findings were seen for other patient subgroups by cancer stages and cancer treatment types. Anti‐viral therapy was associated with a decrease in risk of death, whether started before or after HCC diagnosis (adjusted HR 0.62 and 0.79, respectively; P < 0.001).ConclusionsAnti‐viral therapy improved overall survival in patients with HBV‐related HCC across cancer stages and treatment types but was underutilised at both US and Asia centres. Expanded use of anti‐viral therapy in HBV‐related HCC and better linkage‐to‐care for HBV patients are needed.
Does the Poly (ADP-Ribose) Polymerase Inhibitor Veliparib Merit Further Study for Cancer-Associated Weight Loss? Observations and Conclusions from Sixty Prospectively Treated Patients
Doles, Jason D. , Hogan, Kelly A. , O’Connor, Jennifer M. , Hendrickson, Andrea E. Wahner , Huston, Olivia, Jatoi, Aminah , O'Connor, Jennifer, Wahner Hendrickson, Andrea E, Doles, Jason D

Mayo Clinic

Journal of Palliative Medicine | May 24, 2018 | Volume: 21 | Issue: 9 | Pages: 1334-1338

10.1089/jpm.2018.0023 | PMID 29792535 Get It

Ad5NULL-A20: A Tropism-Modified, αvβ6 Integrin-Selective Oncolytic Adenovirus for Epithelial Ovarian Cancer Therapies
Uusi-Kerttula, Hanni , Davies, James A. , Thompson, Jill , Wongthida, Phonphimon , Evgin, Laura , Shim, Kevin G. , Bradshaw, Angela C. , Baker, Alexander T. , Rizkallah, P.J. , Jones, Rachel, Hanna, Louise , Vile, Richard G. , Chester, John , Parker, Alan L. , Thompson, Jill M, Shim, Kevin G , Parker, Alan L , Rizkallah, Pierre J , Baker, Alexander , Jones, Rachel, Hudson, Emma

Mayo Clinic

Clinical Cancer Research | May 24, 2018 | Volume: 24 | Issue: 17 | Pages: 4215-4224

10.1158/1078-0432.ccr-18-1089 | PMID 29798908 Get It

Abstract Purpose: Virotherapies are maturing in the clinical setting. Adenoviruses (Ad) are excellent vectors for the manipulability and tolerance of transgenes. Poor tumor selectivity, off-target sequestration, and immune inactivation hamper clinical efficacy. We sought to completely redesign Ad5 into a refined, tumor-selective virotherapy targeted to αvβ6 integrin, which is expressed in a range of aggressively transformed epithelial cancers but nondetectable in healthy tissues. Experimental Design: Ad5NULL-A20 harbors mutations in each major capsid protein to preclude uptake via all native pathways. Tumor-tropism via αvβ6 targeting was achieved by genetic insertion of A20 peptide (NAVPNLRGDLQVLAQKVART) within the fiber knob protein. The vector's selectivity in vitro and in vivo was assessed. Results: The tropism-ablating triple mutation completely blocked all native cell entry pathways of Ad5NULL-A20 via coxsackie and adenovirus receptor (CAR), αvβ3/5 integrins, and coagulation factor 10 (FX). Ad5NULL-A20 efficiently and selectively transduced αvβ6+ cell lines and primary clinical ascites-derived EOC ex vivo, including in the presence of preexisting anti-Ad5 immunity. In vivo biodistribution of Ad5NULL-A20 following systemic delivery in non–tumor-bearing mice was significantly reduced in all off-target organs, including a remarkable 107-fold reduced genome accumulation in the liver compared with Ad5. Tumor uptake, transgene expression, and efficacy were confirmed in a peritoneal SKOV3 xenograft model of human EOC, where oncolytic Ad5NULL-A20–treated animals demonstrated significantly improved survival compared with those treated with oncolytic Ad5. Conclusions: Oncolytic Ad5NULL-A20 virotherapies represent an excellent vector for local and systemic targeting of αvβ6-overexpressing cancers and exciting platforms for tumor-selective overexpression of therapeutic anticancer modalities, including immune checkpoint inhibitors. Clin Cancer Res; 24(17); 4215–24. ©2018 AACR.
Stimulation Contractility Gradient of a Neuromuscular Choristoma Within the Sciatic Nerve: 2-Dimensional Operative Video
Stone, Jonathan J. , Amrami, Kimberly K. , Carter, Jodi M. , Spinner, Robert J. , Carter, Jodi

Mayo Clinic

Operative Neurosurgery | May 24, 2018 | Volume: 16 | Issue: 1 | Pages: E17-E17

10.1093/ons/opy131 | PMID 29800277 Get It

Abstract Neuromuscular choristoma (NMC) is a rare congenital nerve lesion that is classified by the presence of heterotopic muscle fibers intercalated within nerve fascicles. 1 The presence of NMC typically causes progressive neuropathy and bony/soft tissue undergrowth, often leading to a shortened atrophic limb. 2,3 The typical appearance of NMC on magnetic resonance imaging is an enlarged fusiform nerve that exhibits minimal gadolinium enhancement. 4 While there is increasing documentation of pathognomonic clinical and radiographic features for various diffuse fusiform peripheral nerve lesions, nerve biopsy is still occasionally required for some patients given the rarity of these diseases and progressive neuropathic features. The intraoperative appearance of NMC and its unique electrical stimulation properties are quite interesting. Intrafascicular replacement of nerve by skeletal muscle gives the nerve a red beefy color and causes the fascicles to contract with electrical stimulation. 5 In this video, we demonstrate the intraoperative appearance and contractile properties of NMC in a 60-yr-old woman with progressive sciatic neuropathy. Histologic and immunohistochemical studies identified a gradient of intralesional mature skeletal muscle within the NMC, with substantially fewer desmin-positive skeletal muscle fibers in the distal aspect. A gradient of contractility with intraoperative stimulation seemed to correlate with this pathology. These findings suggest that the lesional extent of NMC may not be clinically or grossly evident, reflecting a varying distribution of skeletal muscle within the affected nerve. The Mayo Clinic Institutional Review Board Office for Human Research Protection does not require approval for single participant case studies. The subject involved in this study was not identifiable and the general surgical consent form included permission for intraoperative photos and video.
A fatty link between heart disease and autoimmunity
Zeng, Hu

Mayo Clinic

Science Translational Medicine | May 23, 2018 | Volume: 10 | Issue: 442 | Pages: No page available

10.1126/scitranslmed.aat8535 Get It

Atherogenic hyperlipidemia drives IL-27 production by dendritic cells to support follicular T cell differentiation and systemic autoimmune disorders in mice.
Reassessment of the Transport Mechanism of the Human Zinc Transporter SLC39A2
Franz, Marie C., Pujol‐Giménez, Jonai , Montalbetti, Nicolás , Fernández-Tenorio, Miguel , DeGrado, Timothy R. , Niggli, Ernst , Romero, Michael F. , Hediger, Matthias A. , Romero, Michael F , Franz, Marie-Christine

Mayo Clinic

Biochemistry | May 23, 2018 | Volume: 57 | Issue: 26 | Pages: 3976-3986

10.1021/acs.biochem.8b00511 | PMID 29791142 Get It

Patient informaticians: Turning patient voice into patient action
Petersen, Carolyn , Petersen, Carolyn

Mayo Clinic

JAMIA Open | May 23, 2018 | Volume: 1 | Issue: 2 | Pages: 130-135

10.1093/jamiaopen/ooy014 | PMID 31984326 Get It

AbstractHistorically, patients have held a passive role within healthcare, seeking consultation from and following the directions of providers and their care teams. However, changes in culture, education, and technology are making it possible for patients to proactively develop and implement technologies and approaches for health management and quality of life enhancement—to act as patient informaticians. This perspective reviews the societal shifts facilitating the evolution of patient informaticians as discrete actors within healthcare, describes the work of patient informaticians and how this work differs from that of other patient roles (eg, patient advocates), considers examples of patient informaticians in action, and defines patient informaticians’ position relative to the healthcare system.